MCM
BNTC icon

MAI Capital Management’s Benitec Biopharma BNTC Stock Holding History

MAI Capital Management’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$54 Buy
+5
New +$58 ﹤0.01% 4854

Other funds holding BNTC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

MAI Capital Management's BNTC Position: Q1 2026 in Review

MAI Capital Management opened a new position in Benitec Biopharma (BNTC) in Q1 2026: 5 shares worth $54. The stake represents ﹤0.01% of the portfolio and ranks #4854 among its holdings.

88 funds tracked by Wall St. Rank hold BNTC as of Q1 2026.

  • MAI Capital Management held 5 shares of Benitec Biopharma worth $54 as of Q1 2026.
  • Benitec Biopharma was a new MAI Capital Management position in Q1 2026.
  • Benitec Biopharma made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #4854 holding.
  • 88 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.